THE TUMOR ASSOCIATED ANTIGEN-CA15.3 IN PRIMARY BREAST-CANCER - EVALUATION OF 667 CASES
THE TUMOR ASSOCIATED ANTIGEN-CA15.3 IN PRIMARY BREAST-CANCER - EVALUATION OF 667 CASES
复制标题
DOI：
10.1038/bjc.1991.179
复制
发表时间：
1991-05-01
影响因子：
8.8
通讯作者：
BRUSCAGNIN, G
中科院分区：
文献类型：
--
作者：
GION, M;MIONE, R;BRUSCAGNIN, G
在667例原发性未经治疗的乳腺癌患者和193例对照者中测定了术前血清CA 15.3水平。评价CA 15.3与临床及病理指标的关系。CA 15.3水平与临床分期、T、pT、N及阳性淋巴结数呈高度正相关。CA 15.3与阳性淋巴结数目的密切关系也在406例患者中得到证实，其中检查了10个以上的淋巴结。在无腋窝转移的患者中，CA 15.3水平与肿瘤大小以及阳性淋巴结数量相关。CA 15.3与淋巴结阳性数的关系在406例淋巴结阳性数超过10个的患者中也得到证实。CA 15.3水平与无腋窝转移患者的肿瘤大小以及pT1肿瘤中阳性淋巴结的数量相关。CA 15.3在髓样癌中明显高于导管癌。血清CA15.3与受体状态无相关性。我们得出结论，从目前的研究结果，CA 15.3在原发性未经治疗的乳腺癌是一个标志物的肿瘤负荷，以及局部侵袭的趋势（CA 15.3和淋巴结状态之间的关系，在pT1肿瘤）。
CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours).